Top 50 Biotechnology Angel Investors in Europe in February 2025
A list of 50 angel investors that invest in Biotechnology startups based in Europe. We rank investors based on the number of investments they made in Biotechnology companies from Europe. We update this investor list every month.Top 50 Biotechnology Angel Investors in Europe in February 2025
Investor | Biotechnology Europe investments |
---|---|
Jonathan Milner | 32 |
Nadav Rosenberg | 5 |
Darrin Disley | 4 |
Sake Bosch | 4 |
Charlie Songhurst | 4 |
Bernard Majoie | 4 |
Stefano Bernardi | 4 |
Annie Vereecken | 4 |
Milad Alucozai | 4 |
David Helgason | 3 |
Peder Nielsen | 3 |
Schnidar Harald | 3 |
Jude Gomila | 3 |
Inaki Berenguer | 3 |
Andrew Keys | 3 |
Pierre Drion | 3 |
Nicholas Francis | 3 |
DrPano Kroko Churchill | 3 |
Romain Sautrau | 3 |
Andrea Dusi | 3 |
Taavet Hinrikus | 3 |
Ian Hogarth | 3 |
Per Falholt | 3 |
Holger Hübner | 2 |
Barbara Castellano | 2 |
André-Jacques Auberton-Hervé | 2 |
Paul Forster | 2 |
Thor Bjorgolfsson | 2 |
Xavier Niel | 2 |
Fabio Mondini de Focatiis | 2 |
Detlev Riesner | 2 |
Pratima Aiyagari | 2 |
Gilad Engel | 2 |
Giampaolo Cagnin | 2 |
Hampus Jakobsson | 2 |
Others Others | 2 |
Tim Dempsey | 2 |
Mike Novogratz | 2 |
Robert Kopple | 2 |
Bradley Horowitz | 2 |
Patrick Pichette | 2 |
Bruce Linton | 2 |
Luc Vauterin | 2 |
Leena Niemistö | 2 |
Hugh Grant | 2 |
Sauli Törmälä | 2 |
Nadav Ben-Chanoch | 2 |
Chris Mairs | 2 |
Jon Oringer | 2 |
Vishal Gulati | 2 |
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United Kingdom, United States, Canada
Portfolio highlights
- Quibim — Leading radiomics company pioneering quantitative imaging biomarkers and medical applications in precision medicine.
- Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.
- Exciting Instruments — Exciting Instruments Limited is a joint company founded in Sheffield that combines the software prowess of Bulldozer Limited with Dr. Timothy Craggs' knowledge of single molecules. Through the use of cloud connectivity and real-time data visualisation, we are a genuine science and software partnership on a mission to assist you in streamliningthe procedure for creating discoveries in biophysics, life sciences, drug discovery, and medical diagnostics.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more
Investment focus
- Biotechnology, Artificial Intelligence, Pharmaceutical
- Seed, Pre-Seed, Series A
- United Kingdom, Israel, Singapore
Portfolio highlights
- thymia — Making mental health as objectively measurable as physical health.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
- Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more
Investment focus
- Biotechnology, Health Care, Big Data
- Seed, Series A, Funding Round
- United Kingdom
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Sake Bosch is a Founder and Managing Partner of Prime Ventures since 1999. Sake brings over 25 years of experience in marketing and sales and venture capital to Prime. Prior to founding Prime in 1999, Sake was a Senior Principal at Holland Venture and was responsible for managing investments in technology companies. Sake was involved in many ofthe Holland Venture technology investments including Applicare Medical Imaging (acquired by GE Medical Systems), BWise (acquired by Nasdaq), SQL Systems (acquired by Datastream) and Freecom (acquired by Mitsubishi Kagaku Media). Before joining Holland Venture in 1994, Sake worked as an Independent Corporate Finance Consultant focusing primarily on early stage companies. Prior to this position Sake was a Sales Executive at Securitas Group. Sake started his career in 1989 as a Strategic Market Analyst at VNU. Sake serves on the board of directors of Civolution, 4C, Dealerdirect, Digital Origin, Greetz, Forcare, SaaSPlaza, SlimPay and Takeaway.com. Previous investments include: 3mensio Medical Imaging (acquired by Esaoto), eBuddy (acquired by Booking.com), Global Collect (acquired by General Atlantic), MarketXS (acquired by Markit), Nedstat (acquired by comScore Inc.), Tridion (acquired by SDL) and Watermark (acquired by Qurius). Sake holds an M.Sc. degree in Business Administration as well as a B.A. degree in Management Science and Industrial Engineering.
Show more
Investment focus
- Software, E-Commerce, Biotechnology
- Seed, Series A, Series B
- The Netherlands, France, Israel
Portfolio highlights
- Faircraft — A sustainable, lab-grown alternative to animal leather.
- FononTech — FononTech specializes in impulse printing.It is used to print small electronic circuits for electronic devices.
- Mermade Seafoods — Mermade is a pioneering cellular aquaculture company, bringing a novel approach and mindset for the production of cell based seafood.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Pre-Seed, Funding Round
- United Kingdom, United States, Germany
Portfolio highlights
- Stelia — Stelia stands at the forefront of the AI infrastructure revolution and is driving the transition from Internet 2.0, designed for data movement, to Internet 3.0, designed for data mobility, enabling the seamless flow and processing of data across diverse environments. With its ground-breaking HyperBand platform, Stelia enables businesses toharness the full potential of AI. The company's mission is to become the backbone of the next generation of data mobility, empowering organizations across industries to accelerate innovation, optimize operations, and drive transformative growth. Stelia will be at the gravitational centre of the AI infrastructure ecosystem – a trusted partner and catalyst for change that brings together forward-thinking businesses, technology leaders, and industry experts to shape the future of AI. It was founded in 2021 and is located in London, United Kingdom.
- Lodestar — Lodestar is a next-gen robotics company building a fully-integrated solutions to construct, restore and protect high-value assets in space.
- Briefcase — Briefcase automates the legwork in accounting so you can focus on growing your practice
Bernard Majoie - President @ Fournier-Majoie
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Pre-Seed, Series A
- France, Belgium
Portfolio highlights
- reMYND — Driving the development of disease-modifying treatments
- AgenT — AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms.
- PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more
Investment focus
- Software, Biotechnology, Artificial Intelligence
- Seed, Pre-Seed, Funding Round
- Italy, France, Norway
Portfolio highlights
- Freatic — Building the monetization layer for your alpha
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- CaSRevolution — A novel disease-modifying approach against neurodegeneration
Annie Vereecken
Show more
Investment focus
- Biotechnology, Medical, Hospital
- Seed, Series A, Funding Round
- Belgium
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Pre-Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
David is a technologist, the founder of Unity Technologies, non-exec director to others, and a restless entrepreneur with a passion for creating feedback loops between innovation and teams and products, applying new and old business models to changing industries, and pushing people to do the very best they can do.David's background is inprogramming, an assortment of university dabbling, creating companies, and helping entrepreneurs. He served as CEO of Unity Technologies since co-founding it in 2003 and until October 2014, with an unflinching vision to democratize game development, and to develop technology and business models for the next phase of the games industry. David Helgason attended the University of Copenhagen.
Show more
Investment focus
- Software, Gaming, Information Technology
- Seed, Funding Round, Pre-Seed
- United States, Denmark, Finland
Portfolio highlights
- Isometric — Isometric is a carbon removal standard and registry.
- Slope — We handle the lending, underwriting, debt collection and fully pay out to you immediately once the product or service ships.
- Rocky Road — At Rocky Road, we are redefining social gaming with our social gaming network. We are hiring!
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more
Investment focus
- Biotechnology, Machine Learning
- Seed, Funding Round
- United Kingdom
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Entrepreneur, Angel Investor, Scientist and Inventor
Show more
Investment focus
- mHealth, Software, Biopharma
- Seed, Angel, Pre-Seed
- Austria
Portfolio highlights
- SCARLETRED — SCARLETRED is an international Digital Health Scaleup revolutionising the global skin care market by the AI powered SCARLETRED®VISION platform system. The problem we solved is subjective skin assessment and lacking standardization in Dermatology. Our medical device certified platform is fully mobile, runs via mobile App on smartphones and connectsto our web platform, which enables to generate smart imaging data and novel AI decision support applications in Dermatology and Telemedicine. The multi award winning technology is supplied international via SaaS to Biopharma and Cosmetics Industry, Hospitals and Medical Experts. Protected via worldwide patents it facilitates standardized skin documentation and remote tracking of skin changes and therapeutic effects via mobile App. Images can be uploaded in a cloud based platform and objectively analysed for visual skin changes over time, such as for allergic reactions, pigmentation changes, acne, psoriasis, disease or wound healing. SCARLETRED provides services on a broad range of dermatologic conditions ranging from B2B to B2B2C applications.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more
Investment focus
- Software, Biotechnology, Information Technology
- Seed, Pre-Seed, Angel
- United States, United Kingdom, Canada
Portfolio highlights
- Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
- HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more
Investment focus
- E-Commerce, FinTech, Software
- Seed, Angel, Pre-Seed
- Spain, United States, United Kingdom
Portfolio highlights
- Bankflip — Permissioned data technology to collect and process your customers' income, tax, employment & other relevant data & documents in real-time
- Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
- Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.
Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.
Show more
Investment focus
- Software, Finance, Blockchain
- Seed, Pre-Seed, Series A
- United States, India, Norway
Portfolio highlights
- Stackr Labs — Micro-rollups to scale web3 applications
- Zivoe Finance — Join Zivoe in disrupting predatory high-interest lending.
- Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.
Pierre Drion - CEO @ Petercam
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Funding Round
- Belgium
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.
Nicholas Francis is Co-founder at framebunker
Show more
Investment focus
- SaaS, Robotics, Software
- Seed, Series A
- Denmark, United States
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more
Investment focus
- Health Care, Therapeutics, Biotechnology
- Angel, Series A
- United Kingdom
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Romain Sautrau is a Investment Director at Supernova Invest. Romain attended INSEAD.
Show more
Investment focus
- Biotechnology, Agriculture, AgTech
- Series A, Seed, Pre-Seed
- France
Portfolio highlights
- Novolyze — Novolyze is a Food Safety company. They offer solutions to help the food industry manufacture safer food, while ensuring strong compliance with international Food Safety & Quality standards. Their research work mainly focuses on evaluating the inactivation of foodborne pathogens under different kinds of stress (heat, etc.). Based on thisexpertise, they have developed the first range of dried, ready-to-use surrogate bacteria, an innovation that allows the food industry to test the efficacy of microbial kill steps / intervention steps in real-life conditions. At Novolyze, they are at the forefront of Food Safety. Their cross-functional team of experts, mainly composed of food microbiologists and process engineers, is able to assist at multiple stages of a project. Novolyze relies on state-of-the-art infrastructures, installed in a pharmaceutical-grade environment at their R&D Center in Dijon, France.
- Antofenol — Antofénol is a post-harvest biocontrol company that directs and develops its work on the valorization of viticultural waste. Antofénol is an innovative biotechnology start-up providing ecological eco-extraction of plant matter.
- nextProtein — nextProtein is developing a large scale and sustainable insect based source of protein. The bioconversion of fly larvae fed with organic waste generates valuable feed components for fish, livestock and pets.
Entrepreneur and investor.
After working in management consulting, in 2006 he created Wish Days, known above all for the Emozione3 gift boxes. In April 2016, he sold the company to the Smartbox group with a millionaire exit. In 2017, together with Cristina Pozzi, already a partner in Wish Days he founded Impactscool.He is advisor of dozens oftechnological initiatives and business angels in 150+ startups focusing on clean tech.He is the author of the book “Come far fallire una startup ed essere fellici” – How to make a startup fail and be happy, published by Bompiani, Bestseller in 2018.
Show more
Investment focus
- Biotechnology, Health Care, Information Technology
- Seed, Pre-Seed, Series A
- Italy, United States, United Kingdom
Portfolio highlights
- Talyn Air — Inspired by two-stage rockets, our innovative eVTOL uses two flight vehicles to transform flight. Fixed-wing performance with VTOL capabilities.
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- CaSRevolution — A novel disease-modifying approach against neurodegeneration
Taavet Hinrikus is co-founder and CEO of TransferWise. Prior to starting TransferWise, Taavet was Skype’s director of strategy until 2008, starting as its first-ever employee. One of the World Economic Forum's Tech Pioneers, Taavet is an adviser to Prime Minister of Estonia on the digital agenda. He’s also a mentor and angel investor; hisinvestments include Tweetdeck, Mendeley, OMGPOP, Property Partner, Sunrise, Improbable and Mapillary.
Show more
Investment focus
- FinTech, Software, Financial Services
- Seed, Series A, Series B
- United Kingdom, United States, Estonia
Portfolio highlights
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- Open Cosmos — Open Cosmos design, build and operate space missions, providing straightforward access to high quality satellite data and insights on a global scale.
- Unearthly Materials — Unearthly Materials is a transformative materials company focused on delivering practical room-temperature superconductors and powering the century of superconductivity.
Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.
Show more
Investment focus
- Software, E-Commerce, Internet
- Seed, Pre-Seed, Series A
- United Kingdom, United States, Germany
Portfolio highlights
- Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
- Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
- Fabric — One home for your digital world. Your second brain. A file explorer and workspace for the internet age. All your drives, clouds, notes, screenshots, links, and files in one calm, minimal app. No organizing required. Never forget anything again.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more
Investment focus
- Biotechnology, Robotics, Life Science
- Seed, Pre-Seed, Series A
- Denmark
Portfolio highlights
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Holger Hübner
Show more
Investment focus
- B2B, SaaS, Audio
- Seed, Pre-Seed
- Germany
Portfolio highlights
- musicube — Good music deserves to be found. That is why musicube develops revolutionary music search technology. Music streaming services and other companies can forward any user request to musicube and get back high quality data in real time (e.g. to return playlists etc.).
- RetroBrain R&D GmbH — Memore gamifies proven dementia therapies into a gesture controlled medical video game. It incorporates and gamifies proven therapies, delaying the effects of dementia and mild cognitive impairment, enabling elderly people without prior gaming experience to utilize the gaming suite easily.Memore works both therapeutically and preventatively withnursing rehabilitation. It was founded in 2014 and is based in Hamburg, Germany.
- HorseAnalytics — HorseAnalytics empowers horse enthusiasts to monitor and improve health and training of horses by applying reliable technologies from health and sports supervision and combining constant and real-time scientific analytics.
Laura Iris Ferro
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Pre-Seed, Funding Round
- Italy
Portfolio highlights
- Newronika — Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.
- Bio4Dreams — Il primo incubatore italiano certificato di startup innovative in fase very early stage, a capitale totalmente privato, dedicato alle Scienze della Vita.
- CorFlow Therapeutics AG — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Dr. André-Jacques Auberton-Hervé co-founded Soitec with Jean-Michel Lamure in 1992. As President, CEO and Chairman of the Board, Auberton-Hervé is responsible for overseeing the strategic, operational and financial activities of the company.Prior to founding Soitec, Auberton-Hervé managed several joint development programs between Leti andThomson-CSF, which focused on the technological transfer from R&D to production applications. These programs included the transfer of 1.2 µm and 0.8 µm SOI CMOS for space applications. He was also in charge of several projects, which applied SOI to 3D integration, VLSI and ULSI.In July of 2005, Auberton-Hervé was elected to serve as the European representative to SEMI’s International Board of Directors. His demonstrated vision, experience and leadership capabilities within the industry contributed to his appointment to the board. Auberton-Hervé is also the recipient of the 1999 European SEMI Award in recognition of his work on Smart Cut™ technology and his overall contributions to the semiconductor industry as a whole. Auberton-Hervé is a member of the Electrochemical Society and the IEEE.
Show more
Investment focus
- Medical, Biotechnology
- Seed, Series A
- France
Portfolio highlights
- LinKinVax — As part of our strategic evolution, EnnoDC has become the new trading name of LinKinVax. We're expanding our dendritic cell targeting technology and
Paul Forster
Show more
Investment focus
- Software, FinTech, Financial Services
- Seed, Series A, Pre-Seed
- United Kingdom, Germany, United States
Portfolio highlights
- Stackfix — Stackfix operates as a software comparison platform.
- Singulate — The early Hopin team (#1, #4, #30 are cofounders) are back together to solve the biggest problem they saw in events and marketing at Hopin. They’re building a next gen AI marketing platform called Singulate. Singulate provides the easiest way to do audience segmentation and better relevance-personalization for marketing to individuals at scale —results of up to 10X higher CTRs and 5X response rates. They’re helping marketers (in demand gen, growth, community/events) nurture and convert more pipeline from their events and existing customers - it’s not an AI cold outreach sales tool (although it can do reactivations) but rather a lifecycle growth marketing tool. The best personalization is invisible - this is the future of large-scale communication. Get a demo to see the product.
- Purple Dot — Sell More by Selling Earlier
Thor Bjorgolfsson - Entrepreneur, Businessman and Adventure Capitalist Thor Bjorgolfsson, Iceland’s first and only current billionaire, is an investor and business innovator who is not afraid of risk. He has been an entrepreneur since childhood, making his first deal at the age of 10, when he purchased a stack of vintage Marvel comics withborrowed money.In 2004, he founded Novator Partners, an alternative investment firm. He has strategically developed the company to allow it to maintain maximum flexibility as well as to facilitate investments in both strategic (buy and hold) and financial (buy and exit) opportunities.With Novator, Thor leverages private equity as well as macro investments and manages assets across a variety of sectors and geographic locations. He is an active investor in emerging economies including Central and Eastern Europe as well as Latin America.Novator Partners has been a major player in telecom businesses. Thor is a stakeholder in a Polish telecom company called Play, which went public in 2017. In addition, he holds shares in WOM, a Chilean telecommunications firm.Bjorgolfsson’s first fortune was made in post-soviet Russia. At a time when others perceived Russia to be tumultuous, he saw an underserved market that presented an exciting opportunity to invest in great ideas and businesses. He co-founded and developed Bravo Brewery, which produced beer and alcopops. Bravo became one of Russia’s premier brewing companies, particularly through its popular Botchkarov beer brand. Thor sold the business in 2002 to Heineken for $100 million.With the sale of Bravo, he was able to diversify his holdings by reinvesting in new ventures, focusing on telecommunications, pharmaceuticals, and banks. In a few years, he was able to turn that $100 million into a net worth of over $2.1 billion.A year after being featured on the 2007 cover of Forbes Magazine, Iceland went nearly bankrupt overnight and Thor found himself at the epicenter of the financial crisis. As a major shareholder in Landsbanki with personal guarantees of 350m euro, he refused to declare bankruptcy and eventually succeeded in paying off all of it. He then went on to invest in new businesses, re-establishing himself and being featured on the Forbes list of billionaires once again.During this time of rejuvenation, he wrote Billions to Bust and Back: How I Made, Lost and Rebuilt a Fortune, And What I Learned on the Way (2014). In the book, he shares his perspective of what it was like to be at the center of the storm and how he made it back to financial success. He proposes that the greatest strength an entrepreneur can possess is a positive attitude.The 52-year-old Thor was educated in the United States where he earned a Bachelor of Science degree from New York University. In 2005, he was honored as a Young Global Leader by the World Economic Forum. In spite of his intense schedule, Thor enjoys sharing his experience and business insight, making him a sought-after speaker. A multilingual Icelandic citizen, Thor spends most of his time in London, living with his wife and three children. Thor's personal passion is his collection of six motorcycles, which he rides whenever time permits.
Show more
Investment focus
- Big Data, TV, TV Production
- Seed, Series A, Series C
- United Kingdom, Germany
Portfolio highlights
- Olvin — Olvin helps reactive real-world businesses get ahead of the curve and become proactive through the use of its AI powered, predictive analytics platform. Harnessing billions of real world data points, from events and precise location, through to weather and points of interest, Olvin's advanced neural network identifies patterns. Through theuse of both probabilistic and deterministic scoring, Olvin's AI provides actionable insights to brands, retailers and businesses to give them an unparalleled opportunity to delight their customers, identify opportunities and get ahead of potential threats.
- DNEG — We are DNEG, one of the world's leading visual effects and animation studios for feature film and television, honoured with the Academy Award six times
- ATAI Life Sciences — ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Xavier Niel is the Co-Founder and CEO of NJJ Capital. He previously worked at Worldnet as a Founder. Xavier Niel attended Saint Michel de Picpus Catholic private high school.
Show more
Investment focus
- Software, Artificial Intelligence, SaaS
- Seed, Series A, Funding Round
- France, United States, United Kingdom
Portfolio highlights
- Cube — Cube AI boosts back-office logistics efficiency, allowing teams to handle more loads and focus on human relationships.
- Pixmania — Pixmania is an e-commerce website that provides buying and selling of speakers, cameras, headphones, and mobile devices.
- The Mobile-First Company — Early Stage Startup that is Simplifying Business, One App at a Time. Forget about those overcomplicated, pricey software giants. We're building easy, mobile-first tools that actually make sense.
Venture Partner, Eurazeo InvestmentInternational Venture Capitalist, Business Angel and SVP with >20 years experience in >20 countries, with a successful track as VC, BA and Entrepreneur in a truly global environment. Fabio is a Venture Partner in Eurazeo Investment, following their acquisition of IDINVEST Partners, a leading Europeanprivate equity firm with >9B€ AUM, focusing on Venture Capital investments in Italy across sectors and in the Smart City sector (Energy, Cleantech, Eco-mobility) worldwide. Fabio is the Founder and CEO of growth Capital, the leading Italian investment banking focusing on advising innovative, fast-growing companies on fund raising and M&A. Fabio is also an active Business Angel, with a personal portfolio of more than 30 startups. a Member of the Investment Committee of Lazio Innova. Previously Fabio has been a Senior Advisor in the European Investment Fund (EIF), leading the joint efforts of EIF and Cassa Depositi e Prestiti (CDP) to establish TT Investment Funds in Italy to develop its ecosystem for Innovation.
Before entering the Private Equity sector, Fabio has lead Soitec Solar Division sale after it has increased its revenues from ~2M€ to >40M€ and achieved the world record of PV Module Efficiency and Solar Cell Efficiency. He had earlier founded and lead RenEn Renewable Energy to a leading renewable energy consulting firm.
Earlier Fabio has been in McKinsey, ENEL and Russell Reynolds. In ENEL, Fabio has been Head of Integration, Head of International Management, Head of HR and Organisation and member of the Board of various international companies. Fabio received his M.S. degree in Civil and Environmental Engineering from M.I.T. and his M.B.A. from INSEAD. He is fluent in English, Italian, French and Spanish.
Show more
Investment focus
- E-Commerce, Retail, Information Technology
- Seed, Pre-Seed, Equity Crowdfunding
- Italy, France, United Kingdom
Portfolio highlights
- Homepal — Homepal, a digital real estate agency, allows owners and buyers to make direct contact and independently organize visits to the house. It is also a site to buy, sell, and rent a house with the full support of a real estate agency, at low costs. The team of the Homepal RE real estate agency will then help in managing the negotiations and thecontracts.It was founded in 2015 and is headquartered in Italy.
- HiNelson — HiNelson an Italian-based online store for nautical accessories. HiNelson is the first nautical online store about high-level boating components. They select the best and successful brands in the nautical worldwide market, such as Veleria San Giorgio to guarantee maritime safety with their life jackets, moving through Polyform’s boat fenders foryacht protection, or the best anchoring and docking system by Lofrans’, Max Power and Quick and finishing with the most famous Plastimo’s compasses or and Bartomarine sail’s accessories.
- Yobs — Record your interviews, accelerate candidate review, coach recruiters and build a fair and rigorous hiring process.
Prof. Riesner has held the Chair of Biophysics at the Heinrich-Heine-University in Düsseldorf, Germany since 1980 and is Director of Technology at the University of Düsseldorf. He received his Ph.D. from the University of Braunschweig, Germany. Prof. Riesner is also a member of the Supervisory Board and a Director of Qiagen N.V., Netherlands.
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Seed
- Germany
Portfolio highlights
- Numaferm — NUMAFERM challenges this paradigm. We have developed a reliable, cost-efficient manufacturing process that enables the reduction of production costs dramatically (up to 1000x). How is it possible? Our process is based on a well-designed microorganism that converts simple nutrients to peptides. It is the first-in-place bioprocess that serves as areliable platform for the production of peptides; independent of their sequence, length or functionality.
- Pantherna Therapeutics — Pantherna Therapeutics is a biopharmaceutical company developing first-in-class mRNA-LNP therapeutics.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more
Investment focus
- Analytics, Cyber Security, SaaS
- Seed, Pre-Seed, Series A
- United Kingdom, France, Croatia
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Mindflow — Mindflow is a No-Code & AI-driven Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks.
- ESPROFILER — ESProfiler is an enterprise platform that empowers CISOs to prioritise threats, optimise spend & continuously maximise return on investment
Gilad Engel - Partner @ Target Global
Show more
Investment focus
- Hardware, Analytics, Biotechnology
- Seed, Pre-Seed
- France, Israel, United Kingdom
Portfolio highlights
- Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Fourier Optics — Fourier's Metasurface optical combiner seamlessly embeds inside everyday glasses' lenses.
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more
Investment focus
- Biotechnology, Food and Beverage, Plant-Based Foods
- Seed, Pre-Seed
- Italy, Denmark
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.
Show more
Investment focus
- Health Care, Software, Mobile
- Seed, Angel, Series A
- Sweden, Denmark, United States
Portfolio highlights
- ClimateView — ClimateView is a Swedish climate action technology company that helps cities transform climate planning into progress. We combine data, agent-based modelling and interface design to help cities successfully manage the transition to zero carbon economies.
- Mojo — Clinical-grade, AI-powered sperm analysis from the comfort of home. Test your sperm count, motility, morphology and much more with the Mojo kit. Check your fertility from home at low cost - without the need for clinic visits and awkward waiting rooms.
- Volta Greentech — Battling global warming by reducing methane emissions from cows
Others Others
Show more
Investment focus
- Biotechnology, Software, B2B
- Seed, Pre-Seed, Funding Round
- Spain, Germany, Ireland
Portfolio highlights
- Conektto — Design, Build & Test API in minutes. Conektto is the industry's first API SDLC platform that intelligently generates artifacts.
- Gheorg — Around 1 million children in Australia have diagnosable anxiety. Two-thirds of them will never get the help they need. Gheorg is on a mission to change that. We're aiming to reduce childhood anxiety and our new app helps parents and children at home. Sign up to get the app on our website.
- Hooke Bio — Hooke Bio is a new Pharmaceutical company operating in the preclinical to early stages of drug discovery. It draws its strength from the close co-operation it has between its biologists and engineers. The engineers design, patent and test new microfluidic technology: the scientists apply the technology to finding new therapeutics.
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more
Investment focus
- Software, SaaS, Information Technology
- Seed, Series A, Funding Round
- United Kingdom
Portfolio highlights
- Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Michael E. Novogratz is the CEO of Galaxy Investment Partners. He was formerly a principal and a member of the board of directors of Fortress Investment Group LLC and Chief Investment Officer of the Fortress Macro Fund. Mr. Novogratz joined Fortress in 2002 after spending 11 years at Goldman Sachs, where he was elected partner in 1998. Mr.Novogratz founded and serves as the Chairman of the Board for Beat the Streets, a non-profit organization which builds wrestling programs in New York City public schools and is also the Honorary Chairman of USA Wrestling Foundation. Mr. Novogratz is Chairman of The Friends of the Hudson River Park. He also serves on the board of the Acumen Fund, NYU Langone Medical Center, Princeton Varsity Club and The Jazz Foundation of America. Mr. Novogratz received an AB from Princeton University in Economics, and served as a helicopter pilot in the US Army.
Show more
Investment focus
- Blockchain, Cryptocurrency, FinTech
- Seed, Funding Round, Series B
- United States, India, Germany
Portfolio highlights
- Portal — Portal is a financial services company that trades crypto anywhere without putting coins at risk, all from within a controllable wallet. Founded in 2018, Portal is headquartered in San Francisco, California.
- Verandah — Verandah is story based conscious luxury resort brand retailing amongst the top 100 in the global luxury resort wear space with design roots strongly based in India. Verandah also has a line of 100% Italian made sustainable swimwear to compliment the season-less ready to wear line.
- Cambrian Biopharma — Cambrian is developing a raft of new companies and therapies to extend healthy lifespan, bringing proven scientific and organizational expertise to exceptional research teams worldwide.
Robert Kopple
Show more
Investment focus
- FinTech, Finance, Life Science
- Funding Round, Convertible Note
- United States, United Kingdom
Portfolio highlights
- Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
- ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- Mill — Meet the cleanest, easiest way to prevent food waste at home. Mill recycles your peels, bones, stalks, and forgotten leftovers.
- Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
- Overture Life — We are making In Vitro Fertilization (IVF) more accessible than ever before while improving success rates. An embryology lab in a box.
Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).
Show more
Investment focus
- Software, Artificial Intelligence, Machine Learning
- Seed, Series B, Series A
- United Kingdom, Germany, United States
Portfolio highlights
- Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
- Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.
- Unlikely AI — We are pioneering safe, trustworthy and powerful artificial intelligence
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more
Investment focus
- Health Care, Cannabis, Biotechnology
- Seed, Post-IPO Equity, Pre-Seed
- Canada, United States, Denmark
Portfolio highlights
- Omura — Discover heat-not-burn technology with Omura's dry herb vaporizer devices. Explore sustainable vaping options for hemp & whole flower CBD.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Martello Technologies — Prioritize and resolve performance problems and optimize the Microsoft 365 and Teams user experience with Martello Vantage DX.
Luc Vauterin - Board Member @ ONTOFORCE
Show more
Investment focus
- Life Science, Data Integration, Data Visualization
- Seed, Series A
- Belgium
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Leena Niemistö
Show more
Investment focus
- Health Care, Software, E-Commerce
- Seed, Funding Round, Pre-Seed
- Finland, United States
Portfolio highlights
- #Rens — RENS Original is the World's First Sneaker made from recycled coffee and plastic. We know you've been drinking it, now it is time to wear it.
- Maire — Maire is an AI-copilot that helps industry leading B2C companies to detect, understand and monetize emerging online trends
- Finnadvance — Finnadvance is an Organ-On-Chip company developing high throughput biological barriers on chips to mimic human biology such as vascular, lung and the Blood-Brain-Barriers for small molecule, micro-nano-formulation permeability and toxicity testing with in-vivo like dynamic cell cultures.
Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more
Investment focus
- Biotechnology, Machine Learning
- Seed, Funding Round
- United Kingdom
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Sauli Törmälä is the Board Member, CFO at Promilless Oy. He attended University of Oulu.
Show more
Investment focus
- Life Science, Biotechnology
- Seed
- Finland
Portfolio highlights
- Finnadvance — Finnadvance is an Organ-On-Chip company developing high throughput biological barriers on chips to mimic human biology such as vascular, lung and the Blood-Brain-Barriers for small molecule, micro-nano-formulation permeability and toxicity testing with in-vivo like dynamic cell cultures.
Nadav Ben-Chanoch
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Pre-Seed, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- micro1 — We help companies hire and manage the best software engineers easily.
- TRIVER — Triver develops online and digital tools to assist and support various financial services. It is based in London, England.
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
Chris Mairs - Venture Partner @ Entrepreneur First
Show more
Investment focus
- Software, FinTech, Financial Services
- Seed, Pre-Seed, Angel
- United Kingdom, United States
Portfolio highlights
- VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
- Briefcase — Briefcase automates the legwork in accounting so you can focus on growing your practice
- Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Jon Oringer is the founder and chairman of Shutterstock.
Show more
Investment focus
- Software, Information Technology, E-Commerce
- Seed, Pre-Seed, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
- Zamp — We take care of sales tax, so you don't have to.
- NewHomesMate — Find, compare and buy a new construction home - all in one place.
Vishal Gulati: Vishal serves as a venture partner specialising in digital health at DFJ Esprit, Europe's leading Silicon Valley style venture capital firm with over $1b under management. Since 2012, Vishal has been Europe’s leading promoter of investment into the emerging digital health sector and chairman of Digital Health Forum, whichsupports the best in class digital health companies to grow into global enterprises. Vishal serves on several boards including Horizon Discovery Group PLC (Cambridge, UK), a gene editing company; Fluidics Analytics (Cambridge, UK), a next gen protein discovery engine, Frameshift a healthcare information flow platform (London, UK) and EcoEos (San Francisco, USA), a consumer genomics business. His previous investments include Napo Pharmaceuticals, Glenmark, Renovo and Phagenesis.
Show more
Investment focus
- Biotechnology, Biopharma, Life Science
- Seed, Series A, Series B
- United Kingdom, Hungary
Portfolio highlights
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
- evonetix — Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.
- Turbine — Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer.
Investors by industry
Biotech
Energy
Health Care
Hardware
Gaming
Google
Artificial intelligence
Climate
Proptech
Community
FinTech
Consumer
Marketplace
Impact
EdTech
Sustainability
Venture Capital
Retail
Clean Energy
Finance
Education
Organic Food
Big Data
Web3
Food and Beverage
Financial Services
Payments
B2B
Real Estate
Publishing
Video Games
Beauty
Infrastructure
Photography
Medical
Social Network
Wellness
Music
Franchise
Mobile
Internet
Legal
Android
eSports
Construction
Sports
Enterprise Software
Social Media
Email
Art
Digital Media
Manufacturing
Local
Cannabis
Biotechnology
Recruiting
Fitness
Hospitality
Platforms
Mobile Advertising
Travel
Automotive
Wine And Spirits
Medical Device
Crowdfunding
Social
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
LGBT
Oil and Gas
Fashion
Theatre
Life Science
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Social Impact
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
United Kingdom
Germany
United States
South Korea
Canada
Ireland
Australia
New Zealand
Oceania
LATAM
Africa
Asia
Japan
Saudi Arabia
China
Singapore
Spain
Vietnam
Armenia
South Africa
Middle East
Sri Lanka
Brazil
Indonesia
Europe
Qatar
Liechtenstein
Faroe Islands
Barbados
Denmark
Chile
Ecuador
Morocco
Ethiopia
Estonia
Hong Kong
France
Gibraltar
Costa Rica
Greece
Finland
Croatia
Egypt
Georgia
Algeria
Ghana
Bulgaria
Bermuda
Hungary
Czech Republic
Bahrain
Belize
Belgium
Belarus
Serbia
Ukraine
Uganda
Uzbekistan
Thailand
Portugal
Senegal
Liberia
Sierra Leone
Venezuela
Russian Federation
Tajikistan
Rwanda
Zimbabwe
Zambia
Lebanon
Seychelles
Taiwan
Sweden
El Salvador
Tunisia
San Marino
Poland
Turkey
Puerto Rico
Uruguay
Slovenia
Togo
Tanzania
Dominican Republic
Lithuania
Iraq
Nigeria
Bahamas
Namibia
Azerbaijan
Iceland
Kuwait
United Arab Emirates
Jamaica
Honduras
Philippines
Isle of Man
Bolivia
Luxembourg
Pakistan
Albania
Mexico
Bangladesh
Grenada
Romania
Jordan
Argentina
Norway
Jersey
Mauritius
Israel
Malaysia
Peru
Malta
Myanmar
Italy
Mali
Nicaragua
Panama
Kazakhstan
Kenya
Cayman Islands
Cambodia
Guatemala
Latvia
Oman
Cyprus
Cameroon
Austria
Switzerland
Colombia
Marshall Islands
Angel Investors in Europe by industry
Crowdfunding
Restaurants
Venture Capital
Film
Social
Web3
Education
Financial Services
Photography
Cryptocurrency
Finance
Food and Beverage
Wine And Spirits
Medical
Medical Device
Email
Sporting Goods
Social Media
Manufacturing
Digital Media
Art
Music
Mobile
Android
Blockchain
Local
Social Network
Legal
Social Impact
Construction
Software
Sports
Enterprise Software
eSports
Fitness
Automotive
CleanTech
Travel
InsurTech
Mobile Advertising
Platforms
Cannabis
Biotechnology
FinTech
Enterprise
Health Care
Consumer
Video Games
Biotech
Energy
Sustainability
EdTech
Climate
SaaS
Proptech
Marketplace
Community
Hardware
Transportation
Real Estate
Retail
Mobile Apps
Infrastructure
Beauty
Fashion
B2B
Publishing
Big Data
Clean Energy
Oil and Gas
Renewable Energy
Wellness
Impact
Life Science
Recruiting
Internet
Franchise
Gaming
Non Profit
Agriculture (agtech)
Media (entertainment)
Payments
Organic Food
Hospitality
Artificial intelligence